Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide
Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most commonly reported adverse events Study participants receiving up to 30 mg oral ecnoglutide once-daily for 6 weeks achieved a mean body weight reduction of -6.8% from baseline, compared to -0.9% for the placebo group The study remains ongoing to evaluate additional dosing regimens […]